Home / Market News / $BSX
fiscal.ai Corporate Catalyst Impact 75/100 ● neutral

Boston Scientific Reports Third Quarter 2026 Financial Results

Oct 28, 2026, 12:02 PM UTC · Primary ticker $BSX

Boston Scientific reported Q3 2026 financial results, showing modest sales growth and updated its full-year adjusted EPS and net sales guidance. The updated guidance, particularly the projected Q4 sales decline, suggests potential headwinds or conservative forecasting, which could influence investor sentiment.

Boston Scientific announced its third-quarter 2026 financial results, reporting a modest 1.5% increase in net sales and GAAP net income of $0.40 per share. The company also updated its full-year 2026 adjusted EPS and net sales guidance, which is a key driver for investor expectations. The most notable point is the projection of a 1-3% net sales decline for Q4 2026 compared to the prior year, which could be interpreted negatively by the market, despite the full-year sales growth estimate. This could lead to short-term volatility for BSX as investors digest the mixed signals of current growth and future deceleration, potentially impacting its valuation.

$BSX neutral Primary subject of earnings report and guidance update
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.